… the assessment of the effect of tocilizumab. To evaluate the efficacy and safety of early
administration of tocilizumab in hospitalized patients with COVID-19 pneumonia, we designed …

… tocilizumab use. This review will continuously evaluate the role of tocilizumab in COVID-19 …
assess the impact of COVID-19 disease severity on response to tocilizumab therapy. We also …

… Due to the lack of proven therapies, we evaluated the effects of early administration of
tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the …

… use of Tocilizumab (TCZ) in COVID-19 are contrasting and inconclusive. This meta-analysis
aimed to assess TCZ effectiveness in reducing the mortality rate in COVID-19 … on COVID-19 …

… Despite the fact that our findings showed that tocilizumab did not have a positive impact on
COVID-19 patient mortality, we found that tocilizumab was associated with a lower rate of MV …

… In this large observational study, tocilizumab was associated with a lower risk of death or …
While the results of ongoing clinical trials of tocilizumab in patients with COVID-19 will be …

… to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with
… The size of the effects of tocilizumab reported in this paper are therefore an underestimate …

… the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically
ill patients with severe COVID-19 pneumonia. Design: Patients with COVID-19 pneumonia …

… effect of IL-6 in COVID-19 pneumonia, 13 -15 we first evaluated the benefit-risk effect of
tocilizumab (TCZ… Tocilizumab is also approved for systemic inflammatory response caused by the …

… In patients with severe or critical covid-19, tocilizumab plus standard care was not superior
to standard care alone in improving clinical outcomes at 15 days, and it might increase …